Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.
Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; et al.
Pediatric Blood and Cancer.
2021;
68.
Active and Protected: Developing a "Safer Sex " Handout for Adolescents and Young Adults with Cancer.
McGrady, ME; Bredenberg, DL; Danziger-Isakov, L; Rios, J; Frias, O; West, MY; Fisher, P; Salloum, R; Pressey, JG; Norris, RE.
Journal of Adolescent and Young Adult Oncology.
2021;
10:351-354.
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat, VA; Lacayo, NJ; Jabbour, E; Rubnitz, JE; Bajel, A; Laetsch, TW; Leonard, J; Colace, SI; Khaw, SL; Fleming, SA; et al.
Cancer Discovery.
2021;
11:1440-1453.
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy.
Burke, GA A; Beishuizen, A; Bhojwani, D; Burkhardt, B; Minard-Colin, V; Norris, RE; Kabickova, E; Pinarli, FG; Tacyildiz, N; Howes, A; et al.
Leukemia.
2020;
34:2271-2275.
Location of Death and End-of-Life Characteristics of Young Adults with Cancer Treated at a Pediatric Hospital.
Mark, MS J; Yang, G; Ding, L; Norris, RE; Thienprayoon, R.
Journal of Adolescent and Young Adult Oncology.
2019;
8:417-422.
IBRUTINIB + CHEMOIMMUNOTHERAPY (CIT) FOR RELAPSED/REFRACTORY MATURE B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) IN CHILDREN (SPARKLE TRIAL): INITIAL SAFETY, PK, AND EFFICACY.
Burke, A; Beishuizen, A; Bhojwani, D; Burkhardt, B; Minard-Colin, V; Norris, R; Kabickova, E; Pinarli, F; Tacyildiz, N; de Jong, J; et al.
Hematological Oncology.
2019;
37:57-59.
Pediatric acute lymphoblastic leukemia presenting with periorbital edema.
Stein, AP; Norris, RE; Shah, JR.
Otolaryngology Case Reports.
2018;
9:11-14.
Collaborating with Adolescents and Young Adults with Cancer as Advisors.
McGrady, ME; Norris, RE; Pai, AL H.
Journal of Adolescent and Young Adult Oncology.
2018;
7:499-503.
Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
Norris, RE; Fox, E; Reid, JM; Ralya, A; Liu, XW; Minard, C; Weigel, BJ.
Pediatric Blood and Cancer.
2018;
65.